Abbott Laboratories Starts Trial for Device to Treat Mitral Heart Valve Disease

10:48 AM EDT, 10/29/2026 (MT Newswires) -- Abbott Laboratories (ABT) said Thursday it has started a trial assessing the safety and effectiveness of its investigational Cephea mitral valve system to treat people with mitral valve disease who are not candidates for surgery and transcatheter repair. The first enrollment in the study was at Ascension Via Christi Hospital in Wichita, Kansas, the company said. The trial will enroll up to 585 people in the US, Canada and Europe with either leaky mitral valves or mitral valves that are not working properly due to a buildup of calcium in the base of the valves, Abbott said. Price: 103.52, Change: +0.88, Percent Change: +0.86